Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(03): 131-139
DOI: 10.1055/s-0035-1565067
Review
© Georg Thieme Verlag KG Stuttgart · New York

The Emerging Role of Sirtuin 1 in Cellular Metabolism, Diabetes Mellitus, Diabetic Kidney Disease and Hypertension

A. Guclu
1   Division of Nephrology, Kırsehir Training and Research Hospital, Kırsehir/Turkey
,
F. M. Erdur
2   Department of Internal Medicine, Division of Nephrology, N.E. University Meram School of Medicine, Konya/Turkey
,
K. Turkmen
2   Department of Internal Medicine, Division of Nephrology, N.E. University Meram School of Medicine, Konya/Turkey
› Author Affiliations
Further Information

Publication History

received 28 June 2015
revised 20 August 2015

accepted 29 September 2015

Publication Date:
20 November 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Despite diagnostic and therapeutic approaches, diabetic kidney disease (DKD) is the most common cause of end-stage renal disease worldwide. Sirtuins, a group of nicotinamid adenine dinucleotide (NAD) dependent enzymes, can deacetylase target enzymes that regulate a wide variety of cellular processes regarding protein, carbohydrate and lipid metabolism, mitochondrial homeostasis and programmed cell death mechanisms including autophagy and apoptosis. Among sirtuins, sirtuin 1 (SIRT1) has been the most studied one in the pathogenesis and progression of DKD. In recent years, the relation between SIRT1 and hypertension was also evaluated.

In the present review, we aimed to represent the mechanisms of SIRT1 in glucose and lipid metabolism and in the pathogenesis of diabetes mellitus. We also sought to highlight the emerging role of SIRT1 in the pathogenesis and treatment of DKD and hypertension.

Key words

sirtuin1 - apoptosis - autophagy - diabetic kidney disease - hypertension

Next part of this series:

Hypertension and Diabetic NephropathyExp Clin Endocrinol Diabetes 2016; 124(06): 333-334
DOI: 10.1055/s-0042-110231

 

  • References

  • 1 Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008; 31: 596-615
    CrossrefPubMedGoogle Scholar
  • 2 Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 2002; 18 (Suppl. 03) S21-S26
    PubMedGoogle Scholar
  • 3 Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
    CrossrefPubMedGoogle Scholar
  • 4 Gerstein HC, Riddle MC, Kendall DM et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 34i-43i
    PubMedGoogle Scholar
  • 5 Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
    CrossrefPubMedGoogle Scholar
  • 6 Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004; 34: 785-796
    CrossrefPubMedGoogle Scholar
  • 7 Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular disease. J Cardiol 2013;
    PubMedGoogle Scholar
  • 8 Baehrecke EH. Autophagy: dual roles in life and death?. Nat Rev Mol Cell Biol 2005; 6: 505-510
    PubMedGoogle Scholar
  • 9 Kaeberlein M, Kirkland KT, Fields S et al. Sir2-independent life span extension by calorie restriction in yeast. PLoS Biol 2004; 2: E296
    CrossrefPubMedGoogle Scholar
  • 10 Guarente L, Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med 2011; 364: 2235-2244
    CrossrefPubMedGoogle Scholar
  • 11 Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-435
    CrossrefPubMedGoogle Scholar
  • 12 Nogueiras R, Habegger KM, Chaudhary N et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev 2012; 92: 1479-1514
    CrossrefPubMedGoogle Scholar
  • 13 Kitada M, Kume S, Takeda-Watanabe A et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013; 124: 153-164
    CrossrefPubMedGoogle Scholar
  • 14 Vaquero A, Scher M, Erdjument-Bromage H et al. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 2007; 450: 440-444
    CrossrefPubMedGoogle Scholar
  • 15 Walker AK, Yang F, Jiang K et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev 2010; 24: 1403-1417
    CrossrefPubMedGoogle Scholar
  • 16 Purushotham A, Schug TT, Xu Q et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9: 327-338
    CrossrefPubMedGoogle Scholar
  • 17 Rodgers JT, Lerin C, Gerhart-Hines Z et al. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 2008; 582: 46-53
    CrossrefPubMedGoogle Scholar
  • 18 Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007; 282: 34356-34364
    CrossrefPubMedGoogle Scholar
  • 19 Moynihan KA, Grimm AA, Plueger MM et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005; 2: 105-117
    CrossrefPubMedGoogle Scholar
  • 20 Koubova J, Guarente L. How does calorie restriction work?. Genes Dev 2003; 17: 313-321
    CrossrefPubMedGoogle Scholar
  • 21 Nakagawa T, Lomb DJ, Haigis MC et al. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009; 137: 560-570
    CrossrefPubMedGoogle Scholar
  • 22 McCreanor GM, Bender DA. The metabolism of high intakes of tryptophan, nicotinamide and nicotinic acid in the rat. Br J Nutr 1986; 56: 577-586
    CrossrefPubMedGoogle Scholar
  • 23 Rodgers JT, Lerin C, Haas W et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-118
    CrossrefPubMedGoogle Scholar
  • 24 Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426
    CrossrefPubMedGoogle Scholar
  • 25 Liu Y, Dentin R, Chen D et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008; 456: 269-273
    CrossrefPubMedGoogle Scholar
  • 26 Sasaki T, Kim HJ, Kobayashi M et al. Induction of hypothalamic Sirt1 leads to cessation of feeding via agouti-related peptide. Endocrinology 2010; 151: 2556-2566
    CrossrefPubMedGoogle Scholar
  • 27 Puigserver P, Rhee J, Donovan J et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555
    CrossrefPubMedGoogle Scholar
  • 28 Koo SH, Flechner L, Qi L et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005; 437: 1109-1111
    CrossrefPubMedGoogle Scholar
  • 29 Yeagley D, Guo S, Unterman T et al. Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription. Roles of forkhead and insulin response sequences. J Biol Chem 2001; 276: 33705-33710
    CrossrefPubMedGoogle Scholar
  • 30 Ayala JE, Streeper RS, Desgrosellier JS et al. Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. Diabetes 1999; 48: 1885-1889
    CrossrefPubMedGoogle Scholar
  • 31 Inoue H, Ogawa W, Ozaki M et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168-174
    CrossrefPubMedGoogle Scholar
  • 32 Banks AS, Kon N, Knight C et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008; 8: 333-341
    CrossrefPubMedGoogle Scholar
  • 33 Bordone L, Cohen D, Robinson A et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007; 6: 759-767
    CrossrefPubMedGoogle Scholar
  • 34 Bordone L, Motta MC, Picard F et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006; 4: e31
    CrossrefPubMedGoogle Scholar
  • 35 Imai S, Johnson FB, Marciniak RA et al. Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. Cold Spring Harb Symp Quant Biol 2000; 65: 297-302
    CrossrefPubMedGoogle Scholar
  • 36 Elchebly M, Payette P, Michaliszyn E et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 283: 1544-1548
    CrossrefPubMedGoogle Scholar
  • 37 Sun C, Zhang F, Ge X et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007; 6: 307-319
    CrossrefPubMedGoogle Scholar
  • 38 Hou X, Xu S, Maitland-Toolan KA et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008; 283: 20015-20026
    CrossrefPubMedGoogle Scholar
  • 39 Picard F, Kurtev M, Chung N et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776
    CrossrefPubMedGoogle Scholar
  • 40 Li X, Zhang S, Blander G et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28: 91-106
    CrossrefPubMedGoogle Scholar
  • 41 Kemper JK, Xiao Z, Ponugoti B et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009; 10: 392-404
    CrossrefPubMedGoogle Scholar
  • 42 Wang RH, Li C, Deng CX. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci 2010; 6: 682-690
    PubMedGoogle Scholar
  • 43 Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212: 167-178
    CrossrefPubMedGoogle Scholar
  • 44 Miyazaki R, Ichiki T, Hashimoto T et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28: 1263-1269
    CrossrefPubMedGoogle Scholar
  • 45 Shinmura K, Tamaki K, Ito K et al. Indispensable role of endothelial nitric oxide synthase in caloric restriction-induced cardioprotection against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2015; 308: H894-H903
    CrossrefPubMedGoogle Scholar
  • 46 Rossier BC, Pradervand S, Schild L et al. Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annu Rev Physiol 2002; 64: 877-897
    CrossrefPubMedGoogle Scholar
  • 47 Zhang D, Li S, Cruz P et al. Sirtuin 1 functionally and physically interacts with disruptor of telomeric silencing-1 to regulate alpha-ENaC transcription in collecting duct. J Biol Chem 2009; 284: 20917-20926
    CrossrefPubMedGoogle Scholar
  • 48 Zhong XL, Miao HJ, Fang ZM et al. The Effect of SIRT1 Gene Polymorphisms on Ambulatory Blood Pressure of Hypertensive Patients in the Kazakh Population. Genet Test Mol Biomarkers 2015;
    PubMedGoogle Scholar
  • 49 Vendrell J, Chacon MR. TWEAK: A New Player in Obesity and Diabetes. Front Immunol 2013; 4: 488
    PubMedGoogle Scholar
  • 50 Agrawal NK, Kant S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes 2014; 5: 697-710
    CrossrefPubMedGoogle Scholar
  • 51 Kitada M, Takeda A, Nagai T et al. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011; 2011: 908185
    PubMedGoogle Scholar
  • 52 Yoshizaki T, Milne JC, Imamura T et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29: 1363-1374
    CrossrefPubMedGoogle Scholar
  • 53 Liu R, Zhong Y, Li X et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 2014; 63: 2440-2453
    CrossrefPubMedGoogle Scholar
  • 54 Li C, Cai F, Yang Y et al. Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-beta1 pathway. Eur J Pharmacol 2010; 649: 382-389
    CrossrefPubMedGoogle Scholar
  • 55 Li J, Qu X, Ricardo SD et al. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 2010; 177: 1065-1071
    CrossrefPubMedGoogle Scholar
  • 56 Casalena G, Daehn I, Bottinger E. Transforming growth factor-beta, bioenergetics, and mitochondria in renal disease. Semin Nephrol 2012; 32: 295-303
    CrossrefPubMedGoogle Scholar
  • 57 Papadimitriou A, Silva KC, Peixoto EB et al. Theobromine increases NAD(+)/Sirt-1 activity and protects the kidney under diabetic conditions. Am J Physiol Renal Physiol 2015; 308: F209-F225
    CrossrefPubMedGoogle Scholar
  • 58 Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42
    CrossrefPubMedGoogle Scholar
  • 59 Fujitani Y, Kawamori R, Watada H. The role of autophagy in pancreatic beta-cell and diabetes. Autophagy 2009; 5: 280-282
    CrossrefPubMedGoogle Scholar
  • 60 Tanaka Y, Kume S, Kitada M et al. Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res 2012; 2012: 628978
    PubMedGoogle Scholar
  • 61 Hasegawa K, Wakino S, Simic P et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 2013; 19: 1496-1504
    CrossrefPubMedGoogle Scholar
  • 62 Bible E. Diabetic nephropathy: Sirt1 attenuates diabetic albuminuria. Nat Rev Nephrol 2013; 9: 696
    PubMedGoogle Scholar
  • 63 Ruderman NB, Xu XJ, Nelson L et al. AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab 2010; 298: E751-E760
    CrossrefPubMedGoogle Scholar
  • 64 Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40: 280-293
    CrossrefPubMedGoogle Scholar
  • 65 Polak-Jonkisz D, Laszki-Szczachor K, Rehan L et al. Nephroprotective action of sirtuin 1 (SIRT1). J Physiol Biochem 2013; 69: 957-961
    CrossrefPubMedGoogle Scholar
  • 66 Geetha T, Zheng C, Vishwaprakash N et al. Sequestosome 1/p62, a scaffolding protein, is a newly identified partner of IRS-1 protein. J Biol Chem 2012; 287: 29672-29678
    CrossrefPubMedGoogle Scholar
  • 67 Hartleben B, Godel M, Meyer-Schwesinger C et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010; 120: 1084-1096
    CrossrefPubMedGoogle Scholar
  • 68 Ding DF, You N, Wu XM et al. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol 2010; 31: 363-374
    CrossrefPubMedGoogle Scholar
  • 69 Kitada M, Kume S, Imaizumi N et al. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011; 60: 634-643
    CrossrefPubMedGoogle Scholar
  • 70 Cammisotto PG, Londono I, Gingras D et al. Control of glycogen synthase through ADIPOR1-AMPK pathway in renal distal tubules of normal and diabetic rats. Am J Physiol Renal Physiol 2008; 294: F881-F889
    CrossrefPubMedGoogle Scholar
  • 71 Lee MJ, Feliers D, Mariappan MM et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007; 292: F617-F627
    PubMedGoogle Scholar
  • 72 Cammisotto PG, Bendayan M. Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol 2008; 39: 579-584
    CrossrefPubMedGoogle Scholar
  • 73 Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656
    PubMedGoogle Scholar
  • 74 Dugan LL, You YH, Ali SS et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 2013; 123: 4888-4899
    CrossrefPubMedGoogle Scholar
  • 75 Um JH, Park SJ, Kang H et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-563
    CrossrefPubMedGoogle Scholar
  • 76 Timmers S, Konings E, Bilet L et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622
    CrossrefPubMedGoogle Scholar
  • 77 Caton PW, Nayuni NK, Kieswich J et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol 2010; 205: 97-106
    CrossrefPubMedGoogle Scholar
  • 78 Zheng Z, Chen H, Li J et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012; 61: 217-228
    CrossrefPubMedGoogle Scholar
  • 79 Harada H, Andersen JS, Mann M et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001; 98: 9666-9670
    CrossrefPubMedGoogle Scholar
  • 80 Kume S, Thomas MC, Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012; 61: 23-29
    CrossrefPubMedGoogle Scholar
  • 81 Lloberas N, Cruzado JM, Franquesa M et al Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404
    CrossrefPubMedGoogle Scholar
  • 82 Mori H, Inoki K, Masutani K et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 2009; 384: 471-475
    CrossrefPubMedGoogle Scholar
  • 83 Godel M, Hartleben B, Herbach N et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209
    CrossrefPubMedGoogle Scholar
  • 84 Inoki K, Mori H, Wang J et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121: 2181-2196
    CrossrefPubMedGoogle Scholar
  • 85 Yang Y, Wang J, Qin L et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27: 495-502
    CrossrefPubMedGoogle Scholar
  • 86 Kume S, Uzu T, Horiike K et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010; 120: 1043-1055
    CrossrefPubMedGoogle Scholar
  • 87 Cohen HY, Miller C, Bitterman KJ et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392
    CrossrefPubMedGoogle Scholar
  • 88 Tikoo K, Singh K, Kabra D et al. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008; 42: 397-404
    CrossrefPubMedGoogle Scholar
  • 89 Chuang PY, Xu J, Dai Y et al. In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells. Am J Pathol 2014; 184: 1940-1956
    CrossrefPubMedGoogle Scholar
  • 90 Kume S, Haneda M, Kanasaki K et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 2006; 40: 2175-2182
    CrossrefPubMedGoogle Scholar
  • 91 Kume S, Haneda M, Kanasaki K et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007; 282: 151-158
    CrossrefPubMedGoogle Scholar
  • 92 Zhuo L, Fu B, Bai X et al. NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins-AMPK-mTOR pathway. Cell Physiol Biochem 2011; 27: 681-690
    CrossrefPubMedGoogle Scholar
  • 93 Chuang PY, Dai Y, Liu R et al. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011; 6: e23566
    CrossrefPubMedGoogle Scholar
  • 94 He W, Wang Y, Zhang MZ et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 2010; 120: 1056-1068
    CrossrefPubMedGoogle Scholar
  • 95 Liu GC, Oudit GY, Fang F et al. Angiotensin-(1–7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. Am J Physiol Renal Physiol 2012; 302: F784-F790
    CrossrefPubMedGoogle Scholar
  • 96 Gava E, Samad-Zadeh A, Zimpelmann J et al. Angiotensin-(1–7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 2009; 24: 1766-1773
    CrossrefPubMedGoogle Scholar
  • 97 Giani JF, Burghi V, Veiras LC et al. Angiotensin-(1–7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 2012; 302: F1606-F1615
    CrossrefPubMedGoogle Scholar
  • 98 Mori J, Patel VB, Ramprasath T et al. Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 2014; 306: F812-F821
    CrossrefPubMedGoogle Scholar
  • 99 Hasegawa K, Wakino S, Yoshioka K et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 2008; 372: 51-56
    CrossrefPubMedGoogle Scholar
  • 100 Hasegawa K, Wakino S, Yoshioka K et al. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem 2010; 285: 13045-13056
    CrossrefPubMedGoogle Scholar
  • 101 Kim DH, Jung YJ, Lee JE et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol 2011; 301: F427-F435
    CrossrefPubMedGoogle Scholar
  • 102 Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196
    CrossrefPubMedGoogle Scholar
  • 103 Cote CD, Rasmussen BA, Duca FA et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med 2015; 21: 498-505
    CrossrefPubMedGoogle Scholar
  • 104 Ido Y. Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal 2007; 9: 931-942
    CrossrefPubMedGoogle Scholar
  • 105 Yoshino J, Mills KF, Yoon MJ et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011; 14: 528-536
    CrossrefPubMedGoogle Scholar
  • 106 Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008; 324: 883-893
    PubMedGoogle Scholar
  • 107 Madiraju AK, Erion DM, Rahimi Y et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510: 542-546
    CrossrefPubMedGoogle Scholar
  • 108 Duca FA, Cote CD, Rasmussen BA et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med 2015; 21: 506-511
    CrossrefPubMedGoogle Scholar
  • 109 Civitarese AE, Carling S, Heilbronn LK et al Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007; 4: e76
    CrossrefPubMedGoogle Scholar
  • 110 Shang G, Gao P, Zhao Z et al. 3,5-Diiodo-l-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. Biochim Biophys Acta 2013; 1832: 674-684
    CrossrefPubMedGoogle Scholar
  • 111 Marampon F, Gravina GL, Scarsella L et al. Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis. J Hypertens 2013; 31: 1972-1983
    CrossrefPubMedGoogle Scholar
  • 112 Kitada M, Kume S, Kanasaki K et al Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets 2013; 14: 622-636
    CrossrefPubMedGoogle Scholar